NeuroPace (NPCE) Short term Debt (2020 - 2021)

NeuroPace (NPCE) posted quarterly Short term Debt of $3.6 million for Q1 2021, up 75.72% quarter-over-quarter from $2.0 million in Q4 2020.

NeuroPace (NPCE) Short term Debt (2020 - 2021) Analysis & Trends

NeuroPace's Short term Debt history runs 2 years deep, the most recent figure standing at $3.6 million for Q1 2021.

In Q1 2021, Short term Debt changed N/A year-over-year to $3.6 million; the TTM figure through Mar 2021 stood at $3.6 million (changed N/A YoY), while the FY2020 annual figure was $2.0 million, changed N/A from the prior year.
Short term Debt for Q1 2021 stood at $3.6 million, up from $2.0 million in the prior quarter.
The five-year high for Short term Debt was $3.6 million in Q1 2021, with the low at $2.0 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	199.49 Bn	193.88 Bn	7.27 Bn
2	Stryker	127.80 Bn	124.32 Bn	4.50 Bn
3	Medtronic	118.98 Bn	109.76 Bn	6.41 Bn
4	Boston Scientific	73.58 Bn	73.04 Bn	3.85 Bn
5	Edwards Lifesciences	51.93 Bn	47.68 Bn	1.35 Bn
6	Dexcom	34.34 Bn	32.39 Bn	830.00 Mn
7	GE HealthCare Technologies	33.76 Bn	31.66 Bn	2.18 Bn
8	Koninklijke Philips	26.37 Bn	23.05 Bn	4.55 Bn
9	Steris	23.07 Bn	22.59 Bn	684.20 Mn
10	NeuroPace	463.14 Mn	411.44 Mn	18.91 Mn

Download Data

Date	Value
Mar 31, 2021	3.59 Mn
Dec 31, 2020	2.04 Mn